Observational studyClinical rheumatology2026
Compared effectiveness of TNF inhibitors, JAK inhibitors, and csDMARDs in naïve rheumatoid arthritis patients: a real-world, observational, multi-center, retrospective cohort study in Northwest China.
Observational study in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThe objective of this study is to compare the effectiveness of TNF inhibitors (TNFi), JAK inhibitors (JAKi), and conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) in the treatment of anti-citrullinated peptide antibody-positive (ACPA +) and anti-citrullinated peptide antibody-negative (ACPA -) naïve rheumatoid arthritis (RA) patients.
methodsIn this real-world, observational, multi-center, retrospective cohort study in northwest China, we investigated patients with a diagnosis of RA from October 2023 to August 2025. A total of 563 RA patients who met the 2010 ACR/EULAR classification criteria were included and treated with a TNFi (n = 63), a JAKi group (n = 119), and csDMARDs only (n = 381). All evaluation indicators across treatment groups (TNFi, JAKi, and csDMARDs-only) were analyzed by two-way ANOVA with Sidak's multiple comparison tests.
resultsRA patients receiving TNFi, JAKi, or csDMARDs-only experienced comparable clinical benefits. Both ACPA + and ACPA - patients exhibited similar responses among the three treatment groups, with no significant differences in the improvement of evaluation indicators such as HAQ-DI, VAS, PVAS, DVAS, DAS28_ESR, DAS28_CRP, SDAI, and CDAI. The csDMARDs-only group has the highest drug persistence rate at the 12th month among all groups. There are adverse events in the TNFi and JAKi groups, including one case of urinary tract infection, two cases of gastrointestinal reactions, and two cases of abnormal liver function.
conclusionTNFi, JAKi, and csDMARDs-only exhibit similar efficacy in treating naïve RA patients, irrespective of ACPA status. In naïve RA patients, the initial combination of TNFi or JAKi does not have better clinical benefit.
trial registrationThis trial was retrospectively registered with the Chinese Clinical Trial Registry (ChiCTR, https://www.chictr.org.cn/index.html ), a Primary Registry in the World Health Organization International Clinical Trial Registry Platform (WHO ICTRP), under the identifier ChiCTR2300068472. Key Points • TNFi, JAKi, and csDMARDs-only showed similar effectiveness during 12 months in naïve patients. • ACPA status had no significant effect on the efficacy of TNFi, JAKi, and csDMARDs. • The drug persistence of csDMARDs-only is better than that of JAKi and TNFi within 12 months.
Indexed as
Identifiers
41949710What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.